Entrada Therapeutics Inc (TRDA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Entrada Therapeutics Inc stock (TRDA) is currently trading at $12.05. Entrada Therapeutics Inc PS ratio (Price-to-Sales) is 17.30. Analyst consensus price target for TRDA is $20.00. WallStSmart rates TRDA as Sell.
- TRDA PE ratio analysis and historical PE chart
- TRDA PS ratio (Price-to-Sales) history and trend
- TRDA intrinsic value — DCF, Graham Number, EPV models
- TRDA stock price prediction 2025 2026 2027 2028 2029 2030
- TRDA fair value vs current price
- TRDA insider transactions and insider buying
- Is TRDA undervalued or overvalued?
- Entrada Therapeutics Inc financial analysis — revenue, earnings, cash flow
- TRDA Piotroski F-Score and Altman Z-Score
- TRDA analyst price target and Smart Rating
Entrada Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Entrada Therapeutics Inc (TRDA) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Entrada Therapeutics Inc (TRDA) Key Strengths (2)
76.15% of shares held by major funds and institutions
Trading at 1.44x book value, attractively priced
Supporting Valuation Data
Entrada Therapeutics Inc (TRDA) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -96.50%, a shrinking business
Very expensive at 17.3x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Entrada Therapeutics Inc (TRDA) Detailed Analysis Report
Overall Assessment
This company scores 24/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.44) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (17.30) suggest expensive pricing. Growth concerns include Revenue Growth at -96.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -39.10%, Operating Margin at -3103.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -39.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -96.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TRDA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TRDA's Price-to-Sales ratio of 17.30x trades 73% above its historical average of 10x (62th percentile), historically expensive. The current valuation is 34% below its historical high of 26.15x set in Jul 2023, and 1647% above its historical low of 0.99x in Aug 2025. Over the past 12 months, the PS ratio has expanded from ~1.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Entrada Therapeutics Inc (TRDA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Entrada Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 25M with 97% decline year-over-year.
Key Findings
Debt-to-equity ratio of 0.15 indicates a conservative balance sheet with 93M in cash.
Spending 134% of revenue (34M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 97% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -32M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Entrada Therapeutics Inc.
Bottom Line
Entrada Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Entrada Therapeutics Inc(TRDA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Entrada Therapeutics Inc. (TRDA) is a pioneering biotechnology firm committed to developing transformative therapies for severe diseases with considerable unmet medical needs. Leveraging its proprietary Therapeutics for RNA Delivery (TRADA) platform, the company targets RNA and protein dysfunctions associated with debilitating conditions such as muscular dystrophies and genetic disorders. With a robust clinical pipeline and an emphasis on scientific rigor, Entrada is strategically positioned to advance therapeutic solutions that seek to enhance patient outcomes, supported by a seasoned leadership team focused on innovation in the biopharmaceutical landscape.